EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

Michela Garofalo, Giulia Romano, Gianpiero Di Leva, Gerard Nuovo, Young Jun Jeon, Apollinaire Ngankeu, Jin Sun, Francesca Lovat, Hansjuerg Alder, Gerolama Condorelli, Jeffrey A. Engelman, Mayumi Ono, Jin Kyung Rho, Luciano Cascione, Stefano Volinia, Kenneth Nephew, Carlo M. Croce

Research output: Contribution to journalArticle

300 Citations (Scopus)

Abstract

The involvement of the MET oncogene in de novo and acquired resistance of non-small cell lung cancers (NSCLCs) to tyrosine kinase inhibitors (TKIs) has previously been reported, but the precise mechanism by which MET overexpression contributes to TKI-resistant NSCLC remains unclear. MicroRNAs (miRNAs) negatively regulate gene expression, and their dysregulation has been implicated in tumorigenesis. To understand their role in TKI-resistant NSCLCs, we examined changes in miRNA that are mediated by tyrosine kinase receptors. Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C Iε (PKC-Iε) and sarcoma viral oncogene homolog (SRC). These findings suggest that modulation of specific miRNAs may provide a therapeutic approach for the treatment of NSCLCs.

Original languageEnglish
Pages (from-to)74-82
Number of pages9
JournalNature Medicine
Volume18
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Proto-Oncogene Proteins c-met
MicroRNAs
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Carcinogenesis
Protein-Tyrosine Kinases
Apoptotic Protease-Activating Factor 1
Oncogenes
Cells
Gene encoding
Receptor Protein-Tyrosine Kinases
Gene Expression
Epidermal Growth Factor
Gene expression
Epithelial-Mesenchymal Transition
Protein Kinase C
Sarcoma
Modulation
Apoptosis
gefitinib

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Garofalo, M., Romano, G., Di Leva, G., Nuovo, G., Jeon, Y. J., Ngankeu, A., ... Croce, C. M. (2012). EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nature Medicine, 18(1), 74-82. https://doi.org/10.1038/nm.2577

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. / Garofalo, Michela; Romano, Giulia; Di Leva, Gianpiero; Nuovo, Gerard; Jeon, Young Jun; Ngankeu, Apollinaire; Sun, Jin; Lovat, Francesca; Alder, Hansjuerg; Condorelli, Gerolama; Engelman, Jeffrey A.; Ono, Mayumi; Rho, Jin Kyung; Cascione, Luciano; Volinia, Stefano; Nephew, Kenneth; Croce, Carlo M.

In: Nature Medicine, Vol. 18, No. 1, 01.2012, p. 74-82.

Research output: Contribution to journalArticle

Garofalo, M, Romano, G, Di Leva, G, Nuovo, G, Jeon, YJ, Ngankeu, A, Sun, J, Lovat, F, Alder, H, Condorelli, G, Engelman, JA, Ono, M, Rho, JK, Cascione, L, Volinia, S, Nephew, K & Croce, CM 2012, 'EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers', Nature Medicine, vol. 18, no. 1, pp. 74-82. https://doi.org/10.1038/nm.2577
Garofalo, Michela ; Romano, Giulia ; Di Leva, Gianpiero ; Nuovo, Gerard ; Jeon, Young Jun ; Ngankeu, Apollinaire ; Sun, Jin ; Lovat, Francesca ; Alder, Hansjuerg ; Condorelli, Gerolama ; Engelman, Jeffrey A. ; Ono, Mayumi ; Rho, Jin Kyung ; Cascione, Luciano ; Volinia, Stefano ; Nephew, Kenneth ; Croce, Carlo M. / EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. In: Nature Medicine. 2012 ; Vol. 18, No. 1. pp. 74-82.
@article{c61a676de81145a1804bf44452207b43,
title = "EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers",
abstract = "The involvement of the MET oncogene in de novo and acquired resistance of non-small cell lung cancers (NSCLCs) to tyrosine kinase inhibitors (TKIs) has previously been reported, but the precise mechanism by which MET overexpression contributes to TKI-resistant NSCLC remains unclear. MicroRNAs (miRNAs) negatively regulate gene expression, and their dysregulation has been implicated in tumorigenesis. To understand their role in TKI-resistant NSCLCs, we examined changes in miRNA that are mediated by tyrosine kinase receptors. Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C Iε (PKC-Iε) and sarcoma viral oncogene homolog (SRC). These findings suggest that modulation of specific miRNAs may provide a therapeutic approach for the treatment of NSCLCs.",
author = "Michela Garofalo and Giulia Romano and {Di Leva}, Gianpiero and Gerard Nuovo and Jeon, {Young Jun} and Apollinaire Ngankeu and Jin Sun and Francesca Lovat and Hansjuerg Alder and Gerolama Condorelli and Engelman, {Jeffrey A.} and Mayumi Ono and Rho, {Jin Kyung} and Luciano Cascione and Stefano Volinia and Kenneth Nephew and Croce, {Carlo M.}",
year = "2012",
month = "1",
doi = "10.1038/nm.2577",
language = "English",
volume = "18",
pages = "74--82",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

AU - Garofalo, Michela

AU - Romano, Giulia

AU - Di Leva, Gianpiero

AU - Nuovo, Gerard

AU - Jeon, Young Jun

AU - Ngankeu, Apollinaire

AU - Sun, Jin

AU - Lovat, Francesca

AU - Alder, Hansjuerg

AU - Condorelli, Gerolama

AU - Engelman, Jeffrey A.

AU - Ono, Mayumi

AU - Rho, Jin Kyung

AU - Cascione, Luciano

AU - Volinia, Stefano

AU - Nephew, Kenneth

AU - Croce, Carlo M.

PY - 2012/1

Y1 - 2012/1

N2 - The involvement of the MET oncogene in de novo and acquired resistance of non-small cell lung cancers (NSCLCs) to tyrosine kinase inhibitors (TKIs) has previously been reported, but the precise mechanism by which MET overexpression contributes to TKI-resistant NSCLC remains unclear. MicroRNAs (miRNAs) negatively regulate gene expression, and their dysregulation has been implicated in tumorigenesis. To understand their role in TKI-resistant NSCLCs, we examined changes in miRNA that are mediated by tyrosine kinase receptors. Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C Iε (PKC-Iε) and sarcoma viral oncogene homolog (SRC). These findings suggest that modulation of specific miRNAs may provide a therapeutic approach for the treatment of NSCLCs.

AB - The involvement of the MET oncogene in de novo and acquired resistance of non-small cell lung cancers (NSCLCs) to tyrosine kinase inhibitors (TKIs) has previously been reported, but the precise mechanism by which MET overexpression contributes to TKI-resistant NSCLC remains unclear. MicroRNAs (miRNAs) negatively regulate gene expression, and their dysregulation has been implicated in tumorigenesis. To understand their role in TKI-resistant NSCLCs, we examined changes in miRNA that are mediated by tyrosine kinase receptors. Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C Iε (PKC-Iε) and sarcoma viral oncogene homolog (SRC). These findings suggest that modulation of specific miRNAs may provide a therapeutic approach for the treatment of NSCLCs.

UR - http://www.scopus.com/inward/record.url?scp=84855543629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855543629&partnerID=8YFLogxK

U2 - 10.1038/nm.2577

DO - 10.1038/nm.2577

M3 - Article

C2 - 22157681

AN - SCOPUS:84855543629

VL - 18

SP - 74

EP - 82

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 1

ER -